Elite in Metastatic Brain Tumor

Dr. Jing X. Li

Radiation Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life,

Houston, TX

Offers Telehealth

Elite in Metastatic Brain Tumor

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life,

Houston, TX

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jing Li is a Radiation Oncologist in Houston, Texas. Dr. Li is rated as an Elite provider by MediFind in the treatment of Metastatic Brain Tumor. Her top areas of expertise are Breast Cancer, Lung Cancer, Osteosarcoma, Endoscopy, and Percutaneous Coronary Intervention (PCI).

Her clinical research consists of co-authoring 17616 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 6 articles in the study of Metastatic Brain Tumor.

Specialties

Radiation Oncology

Licenses

Radiology in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Humana

HMO
INDEMNITY
POS
PPO

Locations

MD Anderson
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, Houston, TX 77030

Call: 713-592-5433

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD): A Prospective, Multicenter, Randomized, Controlled Trial

Enrollment Status: Completed

Publish Date: December 01, 2025

Intervention Type: Drug

Study Drugs: Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin

Study Phase: Phase 4

Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-Small Cell Lung Cancer

Enrollment Status: Active_not_recruiting

Publish Date: November 10, 2025

Intervention Type: Biological, Other, Radiation, Procedure

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 1/Phase 2

Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Enrollment Status: Completed

Publish Date: October 31, 2025

Intervention Type: Device, Other

Study Phase: Phase 3

A Phase II Clinical Trial Evaluating the Efficacy of Combining Thermal Ablation and Spine Stereotactic Radiosurgery for Patients With Spine Metastases With Moderate to Severe Epidural Involvement

Enrollment Status: Active_not_recruiting

Publish Date: October 30, 2025

Intervention Type: Other, Radiation, Procedure

Study Phase: Phase 2

A Prospective Phase III Randomized Trial to Compare Stereotactic Radiosurgery vs. Whole Brain Radiation Therapy for >/= 4 Newly Diagnosed Non-Melanoma Brain Metastases

Enrollment Status: Active_not_recruiting

Publish Date: September 15, 2025

Intervention Type: Other, Radiation

Study Phase: Phase 3

A Phase II Trial to Determine Local Control and Neurocognitive Preservation After Initial Treatment With Stereotactic Radiosurgery (SRS) for Patients With >3 Melanoma Brain Metastases

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2025

Intervention Type: Other, Radiation

Study Phase: Phase 2

Stereotactic Radiosurgery (SRS) as Definitive Management for a Limited Number of Small Cell Lung Cancer (SCLC) Brain Metastasis

Enrollment Status: Active_not_recruiting

Publish Date: September 05, 2025

Intervention Type: Radiation, Other

Study Phase: Phase 2

A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases

Enrollment Status: Completed

Publish Date: April 23, 2025

Intervention Type: Radiation, Drug

Study Phase: Phase 3

A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Enrollment Status: Completed

Publish Date: October 26, 2024

Intervention Type: Drug

Study Drugs: Sitravatinib, Tislelizumab

Study Phase: Phase 1/Phase 2

The Multi-center Normal Reference Study of Carotid Artery Ultrafast Pulse Wave Velocity (UFPWV) in Chinese Han Adults (CAR-PWV Study）

Enrollment Status: Unknown

Publish Date: May 29, 2020

Intervention Type: Radiation

Non-invasive Prediction of Esophageal Varices in Liver Cirrhosis: A Multicenter Observational Study

Enrollment Status: Completed

Publish Date: February 04, 2019

Intervention Type: Procedure

A Multi-institutional, Randomized Parallel Controlled, Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Amifostine Every-other-day Regimen and Everyday Regimen From Monday to Friday

Enrollment Status: Unknown

Publish Date: July 13, 2017

Intervention Type: Drug

Study Drug: Amifostine

Study Phase: Phase 2

View 11 Less Clinical Trials

17532 Total Publications

Signal pathway and active compounds of Penicillium griseofulvum against triple-negative breast cancer.

Journal: Journal of Asian natural products research

Published: January 23, 2026

View All 17532 Publications

Similar Doctors

Distinguished in Metastatic Brain Tumor

Dr. Mark J. Amsbaugh

Radiation Oncology

Distinguished in Metastatic Brain Tumor

Dr. Mark J. Amsbaugh

Radiation Oncology

UT Physicians

7777 Southwest Fwy, Suite 840,

Houston, TX

(7.1 miles away)

713-456-8080

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Mark Amsbaugh is a Radiation Oncologist in Houston, Texas. Dr. Amsbaugh is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Metastatic Brain Tumor, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), and ALK-Positive Non-Small Cell Lung Cancer. Dr. Amsbaugh is currently accepting new patients.

Distinguished in Metastatic Brain Tumor

Dr. Caroline W. Chung

Radiation Oncology

Distinguished in Metastatic Brain Tumor

Dr. Caroline W. Chung

Radiation Oncology

MD Anderson

1515 Holcombe Blvd,

Houston, TX

(0.6 miles away)

713-792-6127

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Caroline Chung is a Radiation Oncologist in Houston, Texas. Dr. Chung is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. Her top areas of expertise are Metastatic Brain Tumor, Brain Tumor, Posterior Fossa Tumor, and Primitive Neuroectodermal Tumor (PNET).

Distinguished in Metastatic Brain Tumor

Dr. Angel I. Blanco

Radiation Oncology

Distinguished in Metastatic Brain Tumor

Dr. Angel I. Blanco

Radiation Oncology

Oncology Consultants, P. A.

10405 Katy Fwy, Suite 120,

Houston, TX

(10.3 miles away)

713-722-9660

Languages Spoken:

English, Louisiana Creole French, Spanish

See accepted insurances

Accepting New Patients

Angel Blanco is a Radiation Oncologist in Houston, Texas. Dr. Blanco is rated as a Distinguished provider by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Metastatic Brain Tumor, Radiation Induced Meningioma, Posterior Fossa Tumor, and Meningioma. Dr. Blanco is currently accepting new patients.

VIEW MORE METASTATIC BRAIN TUMOR DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Li's expertise for a condition

ConditionClose